Affiliation:
1. Brooke Army Medical Center, Joint Base San Antonio, Fort Sam Houston, Texas, Uniformed Services University, Bethesda, Maryland, and The Geneva Foundation Tacoma Washington
2. Duke Clinical Research Institute Durham North Carolina
3. Extremity Trauma and Amputation Center of Excellence San Diego California
Abstract
ObjectiveThe primary objective was to describe rates of general and pain‐related psychological distress for individuals with low back pain (LBP) in the Military Health System (MHS). We identified common phenotypes defined by rates of general and pain‐related psychological distress and compared phenotypes on their level of pain interference, physical function, anxiety, and depression.MethodsWe created a cohort from two completed trials assessing nonpharmacological treatment for LBP in the MHS (n = 510 total). The Optimal Screening for Prediction of Referral and Outcome Yellow Flag assessment tool identified the presence of 11 different yellow flags. Latent class analysis (LCA) used yellow flag indicators to identify common psychological phenotypes. We then compared Patient‐Reported Outcomes Measurement Information Systems measures of pain interference, physical function, sleep disturbance, depression, and anxiety across phenotypes.ResultsLCA identified five phenotypes (percentage of the sample): low distress (32%), high distress (27%), poor pain coping and low self‐efficacy (18%), low self‐efficacy and acceptance (14%), and poor pain coping (10%). Highly distressed phenotypes reported higher levels of pain interference, sleep disturbance, depression, and anxiety than those with other phenotypes, whereas the low distress phenotype had significantly lower pain interference and higher physical function scores than those characterized by all other phenotypes.ConclusionThese phenotypes provide opportunities for clinicians and researchers to develop novel LBP treatment pathways tailored to patients with different profiles of psychological distress. Future work is needed to validate their predictive capabilities for clinical outcomes.
Funder
United States Department of Defense